Safety and Efficacy of Adjunct Therapies in Adults With Type 1 Diabetes: Multicenter, Registry Study

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Enrollment: 300

Sponsor: Indiana University

Summary

This will be a multicenter registry-based study to evaluate safety and efficacy of GLP-1RA and SGLTi therapies in adjunct to insulin in adults with type 1 diabetes (T1D) over 1 year. This study will enroll participants who have been prescribed adjunct therapy as part of usual care.

Eligibility Criteria

Inclusion Criteria: * Adults ≥18 years of age * Clinical diagnosis of T1D * GLP-1RA or SGLTi (SGLT-1 and SGLT-2 inhibitors) drug prescribed by their provider for any indication as part of usual care with use for no more than 1 week * Use of CGM and availability of CGM data for 1 month prior to enrollment and expected to be available throughout the study * Willing and able to provide informed consent Exclusion Criteria: * No exclusion criteria other than those not meeting inclusion criteria above

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07676565). StuddyBuddy aggregates publicly available trial information.